Voices
Oriol Mirallas
Oriol Mirallas/X

Oriol Mirallas: Outstanding Path in NSCLC Treatment Landscape

Oriol Mirallas, Medical Oncology Specialist at Vall d’Hebron Institute of Oncology, shared a post on X:

“Outstanding path in NSCLC treatment landscape

  • Cisplatin 1978
  • Carboplatin 1989
  • Gefitnib/Erlotinib ’03/04
  • Nivo/Pembro/Atezo ’15-’17
  •  Osimertinib ’15 and earlier setting in ’24
  •  Dato-Dx ’25

Great review by Jarushka Naidoo.”

Title: 50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic

Authors: Jarushka Naidoo, Abesh Niroula, Dipesh Uprety, Matthew Smeltzer, Nicole Geissen, Raymond U. Osarogiagbon, Mari Mino-Kenudson, Yasushi Yatabe, Kristin Higgins, Aakash Desai, Karen L. Reckamp, Jessica Jiyeong Lin, Stephen V. Liu, Fiona Hegi-Johnson, Nagashree Seetharamu, David Harpole, Martin J. Edelman

Read The Full Article at Journal of Thoracic Oncology.

Oriol Mirallas: Outstanding Path in NSCLC Treatment Landscape

More Posts Featuring Oriol Mirallas.

Aakash Desai Abesh Niroula cancer David Harpole Dipesh Uprety Fiona Hegi-Johnson Jarushka Naidoo Jessica Jiyeong Lin Karen L. Reckamp Kristin Higgins Mari Mino-Kenudson Martin J. Edelman Matthew Smeltzer Nagashree Seetharamu Nicole Geissen OncoDaily Oncology Oriol Mirallas Raymond U Osarogiagbon Stephen V Liu Yasushi Yatabe